Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke
NCT ID: NCT01556854
Last Updated: 2012-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20000 participants
OBSERVATIONAL
2011-07-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objectives of the study are as follows:
* To compare safety of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
* To compare cost-effectiveness of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients
NCT05086874
Efficacy and Safety of Early Initiation of Butylphthalide Treatment in Patients With Acute Ischemic Stroke.
NCT06472921
Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
NCT07260760
Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke.
NCT03413202
Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
NCT02149875
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Assessment of Outcomes:The outcome measures in this study include effectiveness, safety and cost measures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ischemic stroke confirmed by brain CT or MRI within 14 days of the index event
* Neuroprotectents administrated during hospitalization
* Direct admission based on physician evaluation or arrival through the emergency department
* Ability of patient or legally authorized representative (primarily spouse, parents, adult children, otherwise indicated) to provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
yongjun wang
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
yongjun wang
Beijing Tiantan hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tiantan hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011BAI08B02-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.